MedPath

Stepwise medical treatment of Cushing's disease

Recruiting
Conditions
Hypercortisolism due to Cushing's disease
Registration Number
NL-OMON20587
Lead Sponsor
Erasmus MCDpt. of Internal Medicine, Endocrine SectionRotterdamThe Netherlands
Brief Summary

/A

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
16
Inclusion Criteria

1. Both naïve patients with Cushing’s disease and patients with residual hypercortisolism after recent transsphenoidal adenomectomy are eligible for enrolment.

2. Finally, patients with recurrent Cushing’s disease can also be included.

Exclusion Criteria

1. Patients with poorly controlled diabetes mellitus indicated by a HbA1c % > 8.5 %.

2. Patients with a disturbed liver function indicated by serum bilirubin, ALAT, ASAT or alkaline phosphatase levels > 2.5 x ULN.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
- Achievement of normocortisolism
Secondary Outcome Measures
NameTimeMethod
- Improvement of clinical symptoms of Cushing's disease<br /><br>- Quality of life<br /><br>- Glucose tolerance<br /><br>- Pituitary adenoma size<br /><br>- Bone metabolism (bone mineral density, bone formative and resorptive markers)<br /><br>- Hemostasis
© Copyright 2025. All Rights Reserved by MedPath